Symbol
| CLDN3
| contributors: mct/npt - updated : 21-01-2017
|
HGNC name
| claudin 3
|
HGNC id
| 2045
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
in colorectal cancer | tumoral
|  
|  
| --over
|  
|
in 90 p100 of ovarian cancers (Huang 2009) | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | | | |
anti-claudin-3 and -4 bispecific monoclonal antibody shows promise in the development of a diagnostic and therapeutic antibody for cancers | cancer | digestive | colon | |
potential markers and therapy target in colorectal cancer | cancer | reproductive | ovary | |
may be a promising target for antibody-based therapy of ovarian carcinomas | cancer | reproductive | ovary | |
lipidoid-formulated CLDN3 siRNA has potential as a therapeutic for ovarian cancer |
| | | |